Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
NKD-H82Q3 | Human | Biotinylated Human NKG2D / CD314 Protein, Avitag™,His Tag (MALS verified) |
|
|
|
NKD-C5248 | Cynomolgus | Cynomolgus NKG2D / CD314 Protein, His Tag |
|
|
|
NKD-H5257 | Human | Human NKG2D / CD314 Protein, Llama IgG2b Fc Tag, low endotoxin |
|
|
|
NKD-H82F4 | Human | Biotinylated Human NKG2D / CD314 Protein, Avitag™,Fc Tag (MALS verified) |
|
|
|
NKD-HF224 | Human | FITC-Labeled Human NKG2D / CD314 Protein, Fc Tag |
|
|
|
NKD-H5259 | Human | Human NKG2D / CD314 Protein, Mouse IgG2a Fc Tag |
|
|
|
NKD-H5245 | Human | Human NKG2D / CD314 Protein, His Tag |
|
|
|
NKD-H5265 | Human | Human NKG2D / CD314 Protein, Fc Tag (HPLC-verified) |
|
|
Immobilized Cynomolgus NKG2D, His Tag (Cat. No. NKD-C5248) at 5 μg/mL (100 μL/well) can bind Human MICA, Fc Tag (Cat. No. MIA-H5253) with a linear range of 0.2-2 ng/mL (QC tested).
The purity of Biotinylated Human NKG2D Protein, Avitag,His Tag (Cat. No. NKD-H82Q3) is more than 85% and the molecular weight of this protein is around 36-46 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease | Details |
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
QEQ-278 | QEQ-278 | Phase 1 Clinical | Novartis Pharmaceuticals Corp | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |
Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease | Details |
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
QEQ-278 | QEQ-278 | Phase 1 Clinical | Novartis Pharmaceuticals Corp | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |
This web search service is supported by Google Inc.